Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Accumulated Expenses (2016 - 2025)

Macrogenics (MGNX) has disclosed Accumulated Expenses for 14 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 24.22% to $22.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.2 million, a 24.22% decrease, with the full-year FY2025 number at $22.2 million, down 24.22% from a year prior.
  • Accumulated Expenses was $22.2 million for Q4 2025 at Macrogenics, down from $23.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $41.9 million in Q3 2021 to a low of $18.1 million in Q1 2024.
  • A 5-year average of $28.7 million and a median of $28.0 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 35.62% in 2024, then surged 53.39% in 2025.
  • Macrogenics' Accumulated Expenses stood at $33.8 million in 2021, then dropped by 14.09% to $29.0 million in 2022, then dropped by 16.41% to $24.2 million in 2023, then increased by 21.02% to $29.3 million in 2024, then fell by 24.22% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Accumulated Expenses are $22.2 million (Q4 2025), $23.1 million (Q3 2025), and $21.3 million (Q2 2025).